Antibiotics have been pivotal in combating bacterial infections, but the emergence of bacterial biofilms presents a significant challenge. These resilient microbial communities, encased in protective matrices, are a hallmark of chronic infections such as those in cystic fibrosis lungs. Biofilm-associated bacteria exhibit adaptive resistance (tolerance), enduring antibiotic concentrations up to 1000 times higher than those required to target free-floating cells. This tolerance represents a critical obstacle in the fight against antimicrobial resistance.

Currently, no specific treatments effectively target biofilm-associated infections. Compounding the challenge, polymicrobial biofilms—formed by multiple bacterial species coexisting in a shared environment—further complicate disease dynamics and treatment strategies. Our research aims to decipher the complexities of polymicrobial biofilms, investigating their formation, persistence, and resistance mechanisms to uncover new therapeutic approaches.

This work represents a vital step toward addressing one of the most pressing issues in modern medicine: overcoming the resilience of biofilm-associated infections and redefining the future of antibiotic therapies.

CLOSE

Our research leverages an advanced murine skin infection model to drive the development and evaluation of innovative therapeutics addressing the global challenge of antimicrobial resistance. This platform enables us to explore novel approaches, particularly targeting bacterial biofilms, which play a critical role in persistent infections. By unraveling bacterial infection strategies, we aim to develop transformative solutions that redefine treatment paradigms in healthcare.

A key focus of our work is the design of antibiotic-conjugates—engineered formulations that enhance the cellular uptake and efficacy of existing drugs. This approach represents a promising strategy to outmaneuver bacterial resistance mechanisms, offering new avenues to combat antibiotic-resistant pathogens. Our research is poised to contribute to the next generation of antimicrobial innovations, paving the way for improved outcomes in the fight against resistant infections.

CLOSE

Our research focuses on some of the most challenging nosocomial pathogens, including the ESKAPE group (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), as well as the widely prevalent Escherichia coli. These organisms are not only key drivers of hospital-acquired infections but also exemplify the complexities of antimicrobial resistance and disease progression.

By investigating their biology, pathogenicity, and resistance mechanisms, we aim to advance our understanding of these critical pathogens. This work has the potential to inform the development of innovative therapeutic strategies and redefine approaches to managing and treating multidrug-resistant infections.

CLOSE